This evidence primarily comes from real-world data on the use of semaglutide and tirzepatide in T1D patients with concomitant overweight/obesity, although a randomized crossover trial investigating the efficacy of semaglutide in adults with T1D using an automated insulin delivery system has recently been published (discussed later in the manuscript). This evidence concerns the gene INS and obesity disorder.